Pricing Log in Create free account

Aclaris Therapeutics, Inc. (ACRS) vs Adlai Nortye Ltd. Sponsored ADR (ANL)

Aclaris Therapeutics, Inc. and Adlai Nortye Ltd. Sponsored ADR are both Biotechnology companies. Aclaris Therapeutics, Inc. and Adlai Nortye Ltd. Sponsored ADR are of similar size ($562.6M and $550.5M). Across the 9 metrics below, Adlai Nortye Ltd. Sponsored ADR leads on 7 and Aclaris Therapeutics, Inc. on 2.

Valuation

Metric ACRS ANL Biotechnology median
P/E n/m — 10.64
P/S 64.95 — 9.59
P/B 4.29 n/m 2.15
Price to free cash flow n/m n/m 26.07
EV/EBITDA n/m n/m 0.65
EV/Sales 55.12 n/m 9.45
Earnings yield (15.51%) — (34.69%)
Free cash flow yield (11.65%) 0.00% (24.02%)

Profitability

Metric ACRS ANL Biotechnology median
Gross margin 12.90% — 65.59%
Operating margin (1,050.16%) — 0.00%
Net margin (921.50%) — 0.00%
Free cash flow margin (756.50%) 0.00% 0.00%
Return on equity (59.10%) 0.00% (51.96%)
Return on assets (41.07%) 0.00% (46.06%)
Return on invested capital (163.35%) 0.00% 0.00%

Growth

Metric ACRS ANL Biotechnology median
Revenue growth (TTM) (51.04%) — 4.59%
EPS growth (last fiscal year) 69.01% 31.48% 29.88%
Revenue growth, 5-year CAGR 3.84% — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric ACRS ANL Biotechnology median
Debt to equity 0.00 0.12 0.00
Current ratio 3.46 9.55 4.86
Net debt to EBITDA 1.20 (0.05) 1.01

Dividend

Metric ACRS ANL Biotechnology median
Dividend yield — — 0.38%
Payout ratio — — —

Size

Metric ACRS ANL Biotechnology median
Market cap 550.53m 562.63m 174.29m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack